Research & patents
Dr. Diehl’s work is part of the public record: three U.S. patents, a peer-reviewed publication, and two independent clinical studies. Here it is, as reported.
The patents
Three patents were granted to Dr. Diehl by the U.S. Patent Office. These are matters of public record; their titles are reproduced as granted.
- U.S. Patent No. 4,049,824 — granted September 20, 1977, covering cetyl myristoleate.
- U.S. Patent No. 4,113,881 — granted September 12, 1978, titled “Method of Treating Rheumatoid Arthritis.”
- U.S. Patent No. 5,569,676 — granted October 29, 1996, titled “Method for the Treatment of Osteoarthritis.”
The patent titles reflect the language of the filings as granted decades ago. They are presented here as historical record, not as a representation of how the compound may be marketed today.
The publication
Diehl’s core finding was published in a peer-reviewed journal:
Independent clinical studies
Two independent, non-manufacturer-funded studies were later conducted in people. They are older and modest in scale, and one appeared in a practitioner newsletter rather than an indexed journal — context worth keeping in mind. Each is summarized in its own words on its own page:
For context, no common joint ingredient — glucosamine, chondroitin, MSM, hyaluronic acid, curcumin or resveratrol — holds a U.S. patent of this kind tied specifically to Diehl’s methods. That’s a statement about the patent record, not a comparison of effectiveness.
Curious about the compound itself? Read the wider evidence summary on Cetyl-Myristoleate.com.